The present invention relates to shaped, bone fiber-based products and methods to make the same.

The present invention relates to shaped, bone fiber-based products and methods to make the same.

The present invention relates to a process for the production of a reinforced polyamide (rP) in an extruder. In this process, a first mixture (M1), a second mixture (M2) and a third mixture (M3) are added into the extruder, and subsequently at least one carbon material is added to obtain a carbon containing polymerizable mixture (cpM) in the extruder. This carbon containing polymerizable mixture (cpM) is polymerized and subsequently devolatilized to obtain the reinforced polyamide (rP). Furthermore, the present invention relates to the reinforced polyamide (rP) obtainable by the inventive process.

An implantable, autonomously growing medical device is disclosed. The device may have an outer, braided outer element that holds an inner core. Degradation and/or softening of the inner core permits the outer element to elongate, allowing the device to grow with surrounding tissue. The growth profile of the medical device can be controlled by altering the shape/material/cure conditions of the inner core, as well as the geometry of the out element.

An implantable, autonomously growing medical device is disclosed. The device may have an outer, braided outer element that holds an inner core. Degradation and/or softening of the inner core permits the outer element to elongate, allowing the device to grow with surrounding tissue. The growth profile of the medical device can be controlled by altering the shape/material/cure conditions of the inner core, as well as the geometry of the out element.

A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w/w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.

The invention relates to a molding material, consisting of or comprising an organic binder, the organic binder being a wax or comprising a wax; and a filler mixture, the filler mixture comprising or consisting of a mineral filler and a fibrous material, wherein the wax is contained in the molding material in a content of between 3% by weight and 23% by weight, and wherein the mineral filler is contained in the molding material in a content of between 75% by weight and 95% by weight. The invention further relates to a molded part made of such a molding material, a method for producing a molded part, and the use of a molding material for forming a molded part.

A method for manufacturing a fibre reinforced composite by means of a vacuum assisted resin transfer moulding, comprising the steps of placing a fibre material in a mould, placing a flow distribution medium onto the fibre material, and covering the fibre material (1) and the flow distribution medium with a vacuum foil for forming a closed mould cavity between the mould and the vacuum foil is described. It is characterised in using a flow distribution medium with a thickness depending on a pressure gradient over the vacuum foil.

A method for manufacturing a fibre reinforced composite by means of a vacuum assisted resin transfer moulding, comprising the steps of placing a fibre material in a mould, placing a flow distribution medium onto the fibre material, and covering the fibre material (1) and the flow distribution medium with a vacuum foil for forming a closed mould cavity between the mould and the vacuum foil is described. It is characterised in using a flow distribution medium with a thickness depending on a pressure gradient over the vacuum foil.

A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w/w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.